Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05652686 |
| Title | A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Phanes Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Sarah Cannon Research Institute at HealthONE | RECRUITING | Denver | Colorado | 80218 | United States | Details |
| Massachusetts General Hospital | RECRUITING | Boston | Massachusetts | 02114 | United States | Details |
| Dana-Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| University of North Carolina at Chapel Hill | RECRUITING | Chapel Hill | North Carolina | 27599 | United States | Details |
| Sarah Cannon Research Institute University of Oklahoma | RECRUITING | Oklahoma City | Oklahoma | 73104 | United States | Details |
| Mays Cancer Center / University of Texas, San Antonio | RECRUITING | San Antonio | Texas | 78229 | United States | Details |
| NEXT Virginia | RECRUITING | Fairfax | Virginia | 22031 | United States | Details |